Compare PAGSEG Inc (PAGS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PAGSEG Inc vs State Street SPDR S&P Biotech ETF — how do they compare? PAGSEG Inc trades at $11.14 (market cap $2.94B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 3.4× PAGSEG Inc's market cap, and PAGSEG Inc pays a 10.49% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold PAGSEG Inc for 26 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| PAGS | XBI | |
|---|---|---|
Market Cap | $2.94B | $10.11B |
Volume | 4,242,708 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $12.00 | $169.55 |
52-Week Low | $8.44 | $104.99 |
Typical Hold Time | 26 Days | 38 Days |
Enterprise Value | $11.02B | — |
Dividend Yield | 10.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $11.16, up 6.18% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 7.1 and net income margin of 10.45%. Recent Q2 2026 earnings beat expectations at $0.41 per share. The company maintains a dividend yield with a $0.28 payment scheduled for September 2026. Revenue growth remains stable at $20.6B for 2026 with improving profitability.
PAGS presents a compelling value opportunity with attractive valuation multiples and consistent earnings performance. Key risks include competitive pressures in digital banking and macroeconomic sensitivity in Brazil. Analyst consensus is strongly bullish with 15 buy ratings and a $10.70 price target, though the current price exceeds this target, suggesting potential near-term consolidation.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
